Medtronic Shares Outstanding History (MDT)
Medtronic reported 1.28B shares outstanding at the end of fiscal 2026.
View full Medtronic company overviewMedtronic annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-24 | 1.28B | −1.8M | −0.14% |
| 2025 | 2025-04-25 | 1.28B | −29.4M | −2.24% |
| 2024 | 2024-04-26 | 1.31B | −19.5M | −1.46% |
| 2023 | 2023-04-28 | 1.33B | 65,641 | +0.00% |
| 2022 | 2022-04-29 | 1.33B | −14.7M | −1.09% |
| 2021 | 2021-04-30 | 1.35B | 4.3M | +0.32% |
| 2020 | 2020-04-24 | 1.34B | 377,129 | +0.03% |
| 2019 | 2019-04-26 | 1.34B | −13.5M | −1.00% |
| 2018 | 2018-04-27 | 1.35B | −15.2M | −1.11% |
| 2017 | 2017-04-28 | 1.37B | −29.6M | −2.12% |
| 2016 | 2016-04-29 | 1.40B | −22.6M | −1.59% |
| 2015 | 2015-04-24 | 1.42B | 422.6M | +42.31% |
| 2014 | 2014-04-25 | 999.0M | — | — |
Medtronic quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-07-31 | 1.28B | −1.8M | −0.14% |
| Q4 2026 | 2026-04-24 | 1.28B | −1.8M | −0.14% |
| Q3 2026 | 2026-01-31 | 1.28B | 100,362 | +0.01% |
| Q3 2026 | 2026-01-23 | 1.28B | 100,362 | +0.01% |
| Q2 2026 | 2025-10-24 | 1.28B | −568,598 | −0.04% |
| Q1 2026 | 2025-07-25 | 1.28B | −625,375 | −0.05% |
| Q4 2025 | 2025-04-25 | 1.28B | −29.4M | −2.24% |
| Q3 2025 | 2025-01-24 | 1.28B | −46.4M | −3.49% |
| Q2 2025 | 2024-10-25 | 1.28B | −47.6M | −3.58% |
| Q1 2025 | 2024-07-26 | 1.28B | −48.0M | −3.61% |
| Q4 2024 | 2024-04-26 | 1.31B | −19.5M | −1.46% |
| Q3 2024 | 2024-01-26 | 1.33B | −723,263 | −0.05% |
| Q2 2024 | 2023-10-27 | 1.33B | 24,872 | +0.00% |
| Q1 2024 | 2023-07-28 | 1.33B | 1.2M | +0.09% |
| Q4 2023 | 2023-04-28 | 1.33B | 65,641 | +0.00% |
| Q3 2023 | 2023-01-27 | 1.33B | −12.2M | −0.91% |
| Q2 2023 | 2022-10-28 | 1.33B | −14.7M | −1.09% |
| Q1 2023 | 2022-07-29 | 1.33B | −15.4M | −1.14% |
| Q4 2022 | 2022-04-29 | 1.33B | −14.7M | −1.09% |
| Q3 2022 | 2022-01-28 | 1.34B | −4.9M | −0.36% |
| Q2 2022 | 2021-10-29 | 1.34B | −686,045 | −0.05% |
| Q1 2022 | 2021-07-30 | 1.34B | 1.4M | +0.10% |
| Q4 2021 | 2021-04-30 | 1.35B | 4.3M | +0.32% |
| Q3 2021 | 2021-01-29 | 1.35B | 6.7M | +0.50% |
| Q2 2021 | 2020-10-30 | 1.35B | 5.2M | +0.39% |
| Q1 2021 | 2020-07-31 | 1.34B | 2.5M | +0.19% |
| Q4 2020 | 2020-04-24 | 1.34B | 377,129 | +0.03% |
| Q3 2020 | 2020-01-24 | 1.34B | 193,473 | +0.01% |
| Q2 2020 | 2019-10-25 | 1.34B | −5.8M | −0.43% |
| Q1 2020 | 2019-07-26 | 1.34B | −10.9M | −0.81% |
| Q4 2019 | 2019-04-26 | 1.34B | −13.5M | −1.00% |
| Q3 2019 | 2019-01-25 | 1.34B | −14.7M | −1.08% |
| Q2 2019 | 2018-10-26 | 1.35B | −7.4M | −0.55% |
| Q1 2019 | 2018-07-27 | 1.35B | −2.9M | −0.21% |
| Q4 2018 | 2018-04-27 | 1.35B | −15.2M | −1.11% |
| Q3 2018 | 2018-01-26 | 1.36B | −13.6M | −1.00% |
| Q2 2018 | 2017-10-27 | 1.35B | −19.5M | −1.42% |
| Q1 2018 | 2017-07-28 | 1.35B | −27.3M | −1.98% |
| Q4 2017 | 2017-04-28 | 1.37B | −29.6M | −2.12% |
| Q3 2017 | 2017-01-27 | 1.37B | −32.2M | −2.30% |
| Q2 2017 | 2016-10-28 | 1.37B | −33.1M | −2.35% |
| Q1 2017 | 2016-07-29 | 1.38B | −31.7M | −2.24% |
| Q4 2016 | 2016-04-29 | 1.40B | −22.6M | −1.59% |
| Q3 2016 | 2016-01-29 | 1.40B | −24.0M | −1.69% |
| Q2 2016 | 2015-10-30 | 1.41B | — | — |
| Q1 2016 | 2015-07-31 | 1.41B | — | — |
| Q4 2015 | 2015-04-24 | 1.42B | 422.6M | +42.31% |
| Q3 2015 | 2015-01-23 | 1.43B | — | — |
| Q4 2014 | 2014-04-25 | 999.0M | — | — |
Medtronic Share Buyback History
A share buyback, also called a stock repurchase, is when a company uses cash to buy its own shares. Medtronic share buyback history shows the reported cash used for repurchases. Buybacks can reduce shares outstanding, but issuance, stock-based compensation, acquisitions, and stock splits can change the share count separately.
Medtronic used $1.03B to repurchase common stock in fy 2026. Across the latest 5 reported fiscal years, total share repurchases were $9.60B. The latest reported quarter showed $267.0M of share repurchases.
| Fiscal year | Period ended | Share repurchases |
|---|---|---|
| 2026 | 2026-04-24 | $1.03B |
| 2025 | 2025-04-25 | $3.23B |
| 2024 | 2024-04-26 | $2.14B |
| 2023 | 2023-04-28 | $645.0M |
| 2022 | 2022-04-29 | $2.54B |
| 2021 | 2021-04-30 | $652.0M |
| 2020 | 2020-04-24 | $1.33B |
| 2019 | 2019-04-26 | $2.88B |
| 2018 | 2018-04-27 | $2.17B |
| 2017 | 2017-04-28 | $3.54B |
TickerStat uses SEC-reported cash payments for common-stock repurchases. The amounts describe capital returned through buybacks; they are not a forecast or a measure of the number of shares retired.
Medtronic shares outstanding trends
Over the last five fiscal years, Medtronic's shares outstanding moved from 1.35B to 1.28B, a change of −65.2M. The latest reported quarter, Q1 2027, shows 1.28B.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medtronic source filings ↗Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...